| Patent application number | Description | Published |
|---|
| 20090275611 | Compounds Which Modulate The CB2 Receptor - Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R | 11-05-2009 |
| 20100009964 | Compounds Which Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 01-14-2010 |
| 20100029644 | Compounds Which Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the invention are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 02-04-2010 |
| 20100081644 | Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 04-01-2010 |
| 20110034512 | Indazole Compounds As CCR1 Receptor Antagonists - Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 02-10-2011 |
| 20110294808 | Indazole Compounds As CCR1 Receptor Antagonists - Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 12-01-2011 |
| 20110312932 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 12-22-2011 |
| 20120010184 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor - Compounds of formula (I) | 01-12-2012 |
